Microbot Medical Inc
NASDAQ:MBOT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (21.8), the stock would be worth $-4.26 (304% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -10.7 | $2.09 |
0%
|
| Industry Average | 21.8 | $-4.26 |
-304%
|
| Country Average | 21.9 | $-4.27 |
-304%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Microbot Medical Inc
NASDAQ:MBOT
|
140.4m USD | -10.7 | -10.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.5B USD | 65.8 | 57.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
157.7B USD | 29.2 | 24.9 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 21.4 | 35.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.9B USD | 27.5 | 22.4 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
85.4B USD | 29.9 | 24 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 36.9 | 44.4 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 41.4 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 46.1 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.4B USD | 17.6 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.1B USD | 17.1 | 20 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.1 |
| Median | 21.9 |
| 70th Percentile | 36.5 |
| Max | 3 188 432.5 |
Other Multiples
Microbot Medical Inc
Glance View
Microbot Medical, Inc. is a pre-clinical medical device company, which engages in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The company is headquartered in Hingham, Massachusetts and currently employs 17 full-time employees. The company specializes in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Its technological platforms include ViRob, TipCAT, LIBERTY and certain CardioSert assets. The ViRob is an autonomous crawling micro-robot, which can be controlled remotely or within the body. The TipCAT is a disposable self-propelled locomotive device that is specially designed to advance tubular anatomy. LIBERTY is designed to maneuver guidewires and over-the-wire devices, such as microcatheters within the body's vasculature. The company is developing Self-Cleaning Shunt (SCSTM), for the treatment of hydrocephalus and Normal Pressure Hydrocephalus (NPH) using ViRob platform. The company is developing the fully disposable robot for various endovascular interventional procedures using LIBERTY and CardioSert platforms. The company is also focused on the development of a multi generation pipeline portfolio.
